
Stephen Ansell
Articles
-
1 month ago |
nature.com | Nicholas Boddicker |Thomas M Habermann |Andrew Feldman |Rebecca King |Stephen Ansell |Angela Dispenzieri | +9 more
AbstractWe investigated the prevalence of rare inherited pathogenic variants (PV) in 19 cancer predisposition genes regularly included on multi-gene panel testing based on NCCN guidelines and their association with the risk of lymphoid malignancies (LM) overall and by common lymphoma subtypes and multiple myeloma. The study population included newly diagnosed LM cases (N = 6990) and unrelated controls (N = 42,632), excluding individuals with a history of hematologic malignancy.
-
Oct 29, 2024 |
targetedonc.com | Stephen Ansell
Stephen M. Ansell, MD, PhD, chair of the Division of Hematology at Mayo Clinic in Rochester, Minnesota, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma. Additionally, he explains how the treatment for these patients is becoming more personalized.
-
Oct 8, 2024 |
nature.com | Melissa Hopper |Abigail R. Dropik |Janek S. Walker |Jordan E. Krull |Matthew J. Maurer |Zhi-Zhang Yang | +4 more
AbstractThis study sheds light on the pivotal role of the oncoprotein DEK in B-cell lymphoma. We reveal DEK expression correlates with increased tumor proliferation and inferior overall survival in cases diagnosed with low-grade B-cell lymphoma (LGBCL). We also found significant correlation between DEK expression and copy number alterations in LGBCL tumors, highlighting a novel mechanism of LGBCL pathogenesis that warrants additional exploration.
-
Sep 17, 2024 |
targetedonc.com | Stephen Ansell
Stephen M. Ansell, MD, PhD, chair of the Division of Hematology at Mayo Clinic in Rochester, Minnesota, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology (SOHO) Annual Meeting in the advanced stage Hodgkin lymphoma space. Here, Ansell highlights additional discussions from the meeting that are of particular interest to a community oncologist, including how to incorporate immunotherapies in the treatment of patients with lymphomas.
-
Sep 7, 2024 |
onlinelibrary.wiley.com | Stephen Ansell
1 DISEASE OVERVIEW Hodgkin lymphoma (HL) affects ~8570 new patients in the United States each year.1 The disease has a bimodal distribution with an increased incidence in young adults and in patients 55 years and older.2, 3 There are no clearly defined risk factors for the development of this disease and the cause of HL remains unknown.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →